



## **Reminder: Exelixis Announces Webcast of Annual R&D Day on This Thursday, December 1**

November 29, 2011

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 29, 2011-- Exelixis, Inc. (NASDAQ:EXEL) will host its seventh annual R&D Day on Thursday, December 1, 2011, from 9:30 a.m. EST / 6:30 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST, in New York. During the event, Exelixis management will review the clinical development program for cabozantinib and discuss the company's corporate strategy and financial outlook for 2012.

In addition, leading oncology experts will share their perspectives on cabozantinib, as well as the evolving treatment landscapes for castration-resistant prostate cancer and medullary thyroid cancer. Presenters will include:

- Matthew Smith M.D., Ph.D., Professor of Medicine and Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center
- Daniel J. George, M.D., Director of Genitourinary Medical Oncology and Director of the Prostate Clinic, Duke University Medical Center
- Howard Scher, M.D., Chief of the Genitourinary Oncology Service, the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering Cancer Center
- Ethan Basch, M.D., Associate Attending Physician at Memorial Sloan-Kettering Cancer Center
- Steven I. Sherman, M.D., Chair and Naguib Saman Distinguished Professor in Endocrinology and Medical Director, Endocrine Multidisciplinary Center at MD Anderson Cancer Center

The event will be webcast and may be accessed in the Event Calendar page under Investors at [www.exelixis.com](http://www.exelixis.com). It will also be archived at that location for a minimum of 30 days.

### **About Exelixis**

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

Source: Exelixis, Inc.

Exelixis, Inc.  
Charles Butler, 650-837-7277  
Vice President, Investor Relations and Corporate Communications  
[cbutler@exelixis.com](mailto:cbutler@exelixis.com)